BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 26, 2026
Home » Blogs » BioWorld MedTech Perspectives » Rethinking Innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Rethinking Innovation

Nov. 5, 2012
By Omar Ford
CC_symbol_only[1]

If I had to sum up the key take away from Cleveland Clinic's Medical Innovation Summit last week, I would probably say something like this : Innovation is alive and well, but are hospitals and physicians willing to pay for it when capital is so strained?

Nearly every panel that I attended seemed to have that as an underlying theme. Everyone from Cleveland Clinic's own Dr. Joseph Iannotti to Medtronic's CEO Omar Ishrak made statements about innovation in healthcare and the importance of having it present in an environment where capital is limited and dollars are few.

Iannotti made the most recent comment about innovation on the closing day of the summit when he said, "High Cost technology is needed - we need to be more efficient in how we use it."

The Medical Innovation Summit was perhaps in a state of flux this year and not because of Hurricane Sandy and its impact into the proceedings (Kudos for Chris Coburn, the executive director of CCF Innovations – the technology arm of the Cleveland Clinic, his team for shuffling around the speakers and keeping the panel going despite the storm impeding traveling plans for many of the panelists).

But rather, the flux came from the lateral shift to med-tech firms and clinicians proving outcomes in therapy coming into fruition. The result is a shift in the way med-tech firms and clinicians are thinking about innovation.

One thing that was made apparent, was that the additional bells and whistles method that was perhaps touted in years past is fading out. Clinicians want simple tools that can get a job done better than some of the complex offerings out on the market.

Perhaps the greatest sign of this was in the Top 10 Innovations of 2013. From insurance plans to bariatric procedures, innovation is slated to occur much differently than in the past.

Below is the Number 1 Innovation of 2013.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • In the clinic for April 21, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing